Consolidation/maintenance chemotherapy for ovarian cancer.
A recently reported randomized trial has demonstrated that administration of single-agent paclitaxel to women with advanced ovarian cancer who attain a clinically defined complete response to platinum/paclitaxel-based chemotherapy can substantially improve progression-free survival. Whether this strategy will improve overall survival in this clinical setting remains uncertain.
Markman
Maurie
M
Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. markmam@ccf.org
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000627:therapeutic use / Q000633:toxicity; D010984:Platinum / Q000627:therapeutic use / Q000633:toxicity; D016032:Randomized Controlled Trials as Topic; D016387:Women's Health
D000970:Antineoplastic Agents; D010984:Platinum; D017239:Paclitaxel